Ovarian Cancer Coverage from Every Angle

Novel TIE2 Kinase Inhibitor Under Study in Platinum-Resistant Ovarian Cancer

By: Julia Fiederlein
Posted: Sunday, November 1, 2020

In part 1 of a phase Ib/II study conducted by Erika P. Hamilton, MD, of the Sarah Cannon Research Institute-Cancer Centre, Nashville, and colleagues, rebastinib in combination with paclitaxel demonstrated antitumor activity across multiple tumor types. Part 2 of the study includes five cohorts: triple-negative breast cancer, inflammatory breast cancer, platinum-resistant ovarian cancer, endometrial cancer, and carcinosarcoma. Preliminary results from the platinum-resistant ovarian cancer cohort were presented during the European Society for Medical Oncology (ESMO) Virtual Congress 2020 (Abstract 839P).

“Rebastinib is a switch control inhibitor of TIE2 kinase,” the investigators remarked. “TIE2 is expressed in endothelial cells and in some macrophages with proangiogenic, prometastatic, and immunosuppressive properties associated with chemotherapy resistance.”

Part 2 is a Simon 2-stage design; enrollment is ongoing. The study was designed to enroll a total of 18 patients in the first stage and an additional 15 patients in the second stage if at least 5 patients achieved a response. Patients with heavily pretreated advanced or metastatic platinum-resistant ovarian cancer were administered rebastinib in combination with weekly paclitaxel. All patients received at least one prior regimen with paclitaxel or carboplatin. As of March 20, 2020, a total of 20 patients were enrolled.

Of the 17 evaluable patients, 5 achieved a partial response, and 9 had stable disease at 8 weeks. The objective response and clinical benefit rates were 29% and 82%, respectively. A CA-125 response was observed in more than half (62%) of patients.

Most treatment-emergent adverse events were grade 2 or lower; fatigue, nausea, diarrhea, dry mouth, peripheral sensory neuropathy, vomiting, abdominal pain, alopecia, constipation, peripheral edema, and stomatitis were reported. The investigators observed three serious adverse events possibly related to rebastinib: grade 2 reversible muscular weakness, fatigue,; and constipation.

Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.